HOUSE_OVERSIGHT_028420.jpg

v W products.","type":"text"}, {"identifier":" anf-body- 41","inlineTextsStyles":[{"range"™: {"length":258, "start":0},"textstyle":"_ anf-ts- i"}, {"range™: {"length":258,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"In restricting access to Revlimid and Thalomid, Celgene relied on a federal requirement that the distribution of those drugs be tightly regulated because of their dangerous side effects under a program known as Risk Evaluation and Mitigation System, or REMS.", "type": "text"},{"components":[{"caption":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times", "captionComponent": {"text":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times"},"identifier™:"100000006098034 S5ba8b8041267d", "imageldentifier"™:" 32d2f6bc7b8b dbJVabad5d6cab07a43", "Layout": "fullbleed- image", "role":"photo", "type": "scalable image"}, {"identifier":" anf-caption- 4","inlineTextsStyles": [{"range":{"Llength":34,"start":147}, "textStyle":"photo- credit"}],"layout":"default-caption", "role":"caption", "text":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times ","type™:"text"}],"identifier":" anf-container-3", "layout": "image- container", "role":"container", "type":"container"}, {"identifier":" anf-body- 42","inlineTextsStyles":[{"range":{"length":111,"start":0},"textstyle":" anf-ts- i"},{"range"™:{"length":111,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role":"body", "text":"Congress expressly prohibited drug companies from using these programs to block or delay generic drug approval.","type":"text"}, {"identifier":" anf-body- 43","inlineTextStyles":[{"range":{"length":88,"start":0},"textStyle":" anf-ts- i"}, {"range"™:{"length":88,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"Yet, according to three lawsuits filed by generic drug companies, Celgene did just that.","type":"text"}, {"identifier":" anf-body- 44","“inlineTextStyles":[{"range": {"length":315,"start":0},"textstyle":" anf-ts- i"}, {"range"™:{"length":315,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"It began with a simple refusal to distribute samples of their drugs, citing REMS and demanding that generic drug companies provide written confirmation from the F.D.A. permitting Celgene to provide drug samples. In the case of Mylan, one of the generic drug companies that sued Celgene, this process took 19 months.", "type"™:"text"}, {"identifier":" anf-body- 45","inlineTextsStyles":[{"range"™: {"length":251, "start":0},"textstyle":" anf-ts- I"}, {"range"™:{"length":251,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role": "body", "text":"After the generic companies sent approval from the F.D.A., Celgene would request more information before agreeing to distribute the drug. But according to court documents in the Mylan case, these requests were laborious, irrelevant and time consuming.", "type™:"text"}, {"identifier":" anf-body- 46","inlineTextStyles":[{"range": {"length":244,"start":0},"textsStyle":" anf-ts- i"}, {"range"™:{"length":244,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"The voluminous requests from Celgene became a rinse-and- repeat cycle for many of the generic drug companies, according to court documents. Two companies, Lannett and Barr Laboratories, settled with Celgene. Mylande€™s suit will soon head to trial.","type":"text"}, {"identifier":" anf-body- 47","“inlineTextStyles":[{"range": {"length":208, "start":0},"textstyle":" anf-ts- i"}, {"range"™:{"length":208,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role": "body", "text": "aeeThis is really concerning conduct and Celgene is by far the worst offender,d4€ Michael Carrier, a professor at Rutgers Law School who studies patent law, said of Celgeneade™s tactics to delay generic development.", "type": "text"}, {"identifier":" anf-heading4- 4","layout":"heading4","role":"heading4","text":" Campaign attack ads over soaring drug prices", "type™:"text"}, {"additions"™: [{"URL":"https://poll.qu.edu/new-jersey/releas detail ?ReleaseID=2563","range":{"length":27,"start":160},"type"™:"link"}],"identifier":" _anf-body-48", "inlineTextStyles": [{"range"™: {"length":295,"start":0},"textStyle":" anf- ts-1"},{"range"™: {"length":295,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"As the Senate race careens toward the final weeks, the Menendez campaign has seen some troubling signs in recent polling. Despite maintaining a six-point lead, a Quinnipiac poll in August found that 49 percent of New Jersey voters believed that Mr. Menendez a€ewas involved in serious wrongdoing.a4€", "type":"text"}, {"additions": [{"URL":"https://www.youtube.com/watch?v=XE lizocN4sé&feature=youtu.be", "range": {"length":21, "start":150}, "type™:"Link"}, {"URL": "htt HOUSE_OVERSIGHT_028420